EU Policies & Directives

Counterfeit Medicines

Counterfeit Medicines

Coming soon
Cross Border Healthcare

Cross Border Healthcare

On 19 January 2011, the European Parliament voted in favour of the EU Directive on cross-border healthcare, a move hailed on that same day by European Commissioner for Health and…
Clinical Trials

Clinical Trials

A clinical trial in the European Union is defined by Directive 2001/20/EC, as a clinical study that aims to investigate the therapeutic effect(s) of medicinal products that have not yet…
Pharmacovigilance

Pharmacovigilance

It is a well known fact that little is truly known about any medicinal product prior to its entry into the market and interaction with a more diverse population than…
Orphan Drugs

Orphan Drugs

An orphan medicinal product is one that is intended for the diagnosis, prevention or treatment of a condition that affects not more than 5 in 10 000 persons, according to…
Rare Diseases

Rare Diseases

Rare diseases, including those of genetic origin, are life-threatening or chronically debilitating diseases which are of such low prevalence that special combined efforts are needed to address them. As a…
Information to patients

Information to patients

The necessity to amend the Directive on the Information to Patients on Prescribed Medicinal Products (2001/83/EC) arose after the submission of the Commission, on 20 December 2007, of a Communication…
Patients’ safety

Patients’ safety

Coming soon
Blood safety & donation

Blood safety & donation

Visual taken from WHO, World Blood Donor Day 2017 Regular blood transfusions have been a central aspect of the treatment of thalassaemia since the 1960s. As blood transfusion is a lifelong…
Back to top button